金吾财讯 | 三生制药(01530)涨幅扩大，截至发稿，涨36.41%，报19.78港元，成交额29.22亿港元。消息面上，公司与辉瑞就前者专有CLF2平台自主研发的PD-1/VEGF双特异性抗体SSGJ-707签订了独家许可协议 。根据协议，辉瑞将获得SSGJ-707在全球（不包括中国内地）开发、生产和商业化的独家权利 ，集团将收到12.5亿美元的首付款，并可获得总额最多为48亿美元的潜在付款，包括开发、监管批准及销售里程碑付款。上述所有款项均不可退还且不可抵扣。集团亦将就许可地区的产品净销售额收取双位数百分比的梯度特许权使用费。辉瑞应负责承担许可产品在许可地区内的所有未来试验的开发及监管事务的所有费用。另外，据公告，辉瑞将于生效日期根据股份认购协议（“正式协议”）所载条款，按30日成交量加权平均价（视乎适用规则及法规（包括上市规则）的批准及规定而定）认购公司价值1亿美元的普通股（“可能认购事项”），该协议将由订约方于许可协议日期后另行磋商及协定。公司将向辉瑞（或其代名人）配发及发行新股份的确切条款及数目将于正式协议中厘定及最终确定。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.